Helping Cancer Patients with Chronic Pain
Creating Ethical Shareholder Value

About us

We are pioneering the development of pain treatments.

CBD Science is leading the development of cannabis-based treatments for cancer pain in the UK & Europe. 

We are working with world-class physicians, and Britain’s official regulatory authorities to allow the legal availability of new pain treatments, through our Real World Evidence trials. 

01.

UK & Europe

Our trials are conducted on cancer patients, in a clinical setting, using our medicinal cannabis products, starting with the UK and expanding to Europe. 

02.

Real World Evidence

RWE trials are conducted on diagnosed cancer patients suffering from chronic pain. Patient level Clinical Evidence is used to assess the value of treatments based on actual health outcomes.

03.

Safer Pain Medicines

Real-world performance will enable individual management solutions which will lead to the development of safer, more suitable patient pain management programs.

Why Real-World Evidence?

Patient Solutions

Reimbursement Decisions

Regulatory Decisions

Our Team

Meet our expert team.

A diverse team with extensive experience in the Canadian and Californian cannabis market, public company management, Agri-Tech and European pharmaceutical patient access. 

Dr. Michael Raymont

Chief Executive Officer

Mike’s depth of experience in entrepreneurship, venture capital and government relations is evident by his past leadership of AVAC, Canada’s largest Agri-Tech venture capital fund and acting president of National Research Council.

Graeme McFarlane

Chief Commercial Officer

30+ years in the pharmaceutical industry holding senior management positions in Astra Zenca, GlaxoSmithKline and Bristol Myers before starting B2B companies specializing in Pharma Market Access, his most recent having been sold to IQVIA.

Rob Kang

Chief Financial Officer

25+ years of public practice and company management advising corporations and their executives on financing, mergers and acquisitions, going public transaction, continuous disclosure obligations, and corporate governance.

Chief Executive Officer

Mike’s depth of experience in entrepreneurship, venture capital and government relations is evident by his past leadership of AVAC, Canada’s largest Agri-Tech venture capital fund and acting president of National Research Council.

 

Chief Commercial Officer

30+ years in the pharmaceutical industry holding senior management positions in Astra Zenca, GlaxoSmithKline and Bristol Myers before starting B2B companies specializing in Pharma Market Access, his most recent having been sold to IQVIA.

Chief Financial Officer

25+ years of public practice and company management advising corporations and their executives on financing, mergers and acquisitions, going public transaction, continuous disclosure obligations, and corporate governance.

Professor Mike Bewick

Chief Clinical Advisor

Mike is the former Deputy Medical Director at NHS England and has wide-ranging experience including planning, commissioning and providing services, leading clinical management teams on a national basis.

Barney Neal

Chief Operating Officer

Barney is a product & marketing entrepreneur focussing his efforts to enable access to life changing plant medicines for patients in need. Barney has worked closely with the Conscious Fund, a Venture Capital Fund focused on cannabis & psychedelics.

Clinical Advisory Board.

Chief Clinical Advisor

Mike is the former Deputy Medical Director at NHS England and has wide-ranging experience including planning, commissioning and providing services, leading clinical management teams on a national basis.

 

Chief Operating Officer

Barney is a product & marketing entrepreneur focussing his efforts to enable access to life changing plant medicines for patients in need. Barney has worked closely with the Conscious Fund, a Venture Capital Fund focused on cannabis & psychedelics.

Clinical Advisory Board.